Inhibitors of lysine specific demethylase-1
AssigneeCelgene Quanticel Research, Inc.
InventorsYoung K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
Claims17
A method of treating prostate cancer in a patient in need thereof, comprising administering to the patient a therapeutic effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof,
- wherein,
- A is C;
- B is N;
- and D is C—R3;
- R3 is hydrogen;
- W1 and W2 are C—H;
- X is chosen from aryl optionally substituted with halogen, alkyl, or alkoxy;
- or heteroaryl optionally substituted with halogen, alkyl, alkoxy, or cycloalkyl;
- Y is chosen from hydrogen, halogen, alkyl optionally substituted with —OH, alkoxy, or carbonyl;
- and
- Z is N-heterocyclyl optionally substituted with —NH2, amine, or alkyl.
Dependencies are inferred from the claim text.